DOI: 10.1055/s-00023610

Drug Research

Issue 06 · Volume 66 · June 2016 DOI: 10.1055/s-006-31944

Review

  • 281
    Zetner, D.; Andersen, L. P. H.; Rosenberg, J.:

    Melatonin as Protection Against Radiation Injury: A Systematic Review

    Supporting Information (PDF)

    • Original Article

  • 287
    Ebihara, T.; Teshima, K.; Kondo, T.; Tagawa, Y.; Moriwaki, T.; Asahi, S.:

    Pharmacokinetics of TAK-475, a Squalene Synthase Inhibitor, in Rats and Dogs

  • 293
    Tjandrawinata, R. R.; Yunaidi, D. A.; Susanto, L. W.:

    The Safety and Tolerability of Lumbrokinase DLBS1033 in Healthy Adult Subjects

  • 300
    Sheikhi, A.; Shakerian, M.; Giti, H.; Baghaeifar, M.; Jafarzadeh, A.; Ghaed, V.; Heibor, M. R.; Baharifar, N.; Dadafarin, Z.; Bashirpour, G.:

    Probiotic Yogurt Culture Bifidobacterium Animalis Subsp. Lactis BB-12 and Lactobacillus Acidophilus LA-5 Modulate the Cytokine Secretion by Peripheral Blood Mononuclear Cells from Patients with Ulcerative Colitis

  • 306
    Fukata, A.; Yamazaki, T.:

    Comparative Influence of Imidafenacin and Oxybutynin on Voiding Function in Rats with Functional Urethral Obstruction

  • 312
    Idkaidek, N.; Najib, N.; Salem, I.I.; Najib, O.:

    Saliva versus Plasma Relative Bioavailability of Tolterodine in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System

  • 316
    Ebihara, T.; Takeuchi, T.; Moriya, Y.; Tagawa, Y.; Kondo, T.; Moriwaki, T.; Asahi, S.:

    Characterization of Transporters in the Hepatic Uptake of TAK-475 M-I, a Squalene Synthase Inhibitor, in Rats and Humans

  • 324
    Hass, C.; Panda, B. P.; Khanam, R.; Najmi, A. K.; Akhtar, M.:

    Histamine H3 Receptor Agonist Imetit Attenuated Isoproterenol Induced Renin Angiotensin System and Sympathetic Nervous System Overactivity in Myocardial Infarction of Rats

  • 330
    Razavi-Azarkhiavi, K.; Jafarian, A. H.; Abnous, K.; Razavi, B. M.; Shirani, K.; Zeinali, M.; Jaafari, M. R.; Karimi, G.:

    The Comparison of Biodistribution, Efficacy and Toxicity of Two PEGylated Liposomal Doxorubicin Formulations in Mice Bearing C-26 Colon Carcinoma: a Preclinical Study